|Other Names||Activator of apoptosis harakiri, BH3-interacting domain-containing protein 3, Neuronal death protein DP5, HRK, BID3|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1311a was selected from the region of human Hrk BH3 Domain. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Cellular Location||Membrane; Single-pass membrane protein. Mitochondrion|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Activator of apoptosis Hrk regulates apoptosis through interaction with death-repressor proteins Bcl-2 and Bcl-X(L). The HRK protein lacks significant homology to other BCL2 family members except for an 8-amino acid region that was similar to the BCL2 homology domain-3 (BH3) motif of BIK. HRK interacts with BCL2 and BCLXL via the BH3 domain, but not with the death-promoting BCL2-related proteins BAX, BAK, or BCLXS. HRK localizes to membranes of intracellular organelles in a pattern similar to that previously reported for BCL2 and BCLXL.
Wakabayashi, T., et al., Neurosci. Lett. 318(2):77-80 (2002).Inohara, N., et al., EMBO J. 16(7):1686-1694 (1997).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.